Oct 26 (Reuters) - Swiss drugmaker Novartis AG
is close to acquiring U.S. biotech Avidity Biosciences ( RNA )
for over $70 per share, Bloomberg News reported on Sunday,
citing a person familiar with the matter.
Reuters could not immediately confirm the report.